MANKIND - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 2.7

📊 Analysis: Mankind Pharma is trading at ₹2,174, below DMA 50 (₹2,279) and DMA 200 (₹2,402), indicating short-term and medium-term weakness. RSI at 35.3 suggests oversold conditions, but MACD negative (-47.7) confirms bearish momentum. Volume (4.26L) is below 1-week average (6.51L), showing reduced intraday participation. Fundamentals are decent with ROCE 15.0% and ROE 13.9%, but high P/E (53.8 vs industry 30.6), PEG ratio (6.40), and quarterly profit decline (-25.2%) weigh on sentiment. Intraday trades may be possible for speculative rebound near support, but risk is elevated.

💡 Optimal Buy Price: ₹2,160–₹2,175 (near support zone).

🎯 Profit-Taking Levels: ₹2,200 (first target), ₹2,230 (second target).

🛡️ Stop-Loss: ₹2,145 (below intraday support).

⏱️ If Already Holding: Exit near ₹2,200–₹2,230 if rebound occurs. Cut position immediately if price falls below ₹2,145 with rising volume, as weakness may extend further.

Positive

• 📈 ROCE 15.0% and ROE 13.9% show decent efficiency
• 💹 DII holding increased (+0.41%), showing domestic support
• 📊 Quarterly PAT improved from ₹413 Cr. to ₹459 Cr.

Limitation

• 📉 P/E 53.8 much higher than industry average (30.6)
• 📊 PEG ratio 6.40 indicates overvaluation relative to growth
• 📉 Price below DMA 50 & DMA 200, confirming bearish trend
• 📊 Volume below average, limiting intraday momentum

Company Negative News

• ⚠️ Quarterly profit decline (-25.2%) impacting sentiment
• ⚠️ FII holding decreased (-0.24%), showing reduced foreign confidence

Company Positive News

• ✅ DII holding increased (+0.41%), showing domestic institutional support
• ✅ EPS ₹40.4 reflects earnings strength despite valuation concerns

Industry

• 🏥 Industry PE at 30.6, Mankind at 53.8 — relatively overvalued
• 📊 Pharma sector remains defensive but valuations are stretched

Conclusion

🔎 Mankind Pharma is a weak intraday candidate with bearish technicals and stretched valuations, though oversold RSI may trigger short-term rebound. Buy zone is ₹2,160–₹2,175 with targets at ₹2,200 and ₹2,230. Maintain strict stop-loss at ₹2,145. If already holding, exit near targets or cut losses below support with volume confirmation.

Would you like me to extend this into a peer benchmarking overlay with other pharma majors or a sector rotation basket scan to validate intraday opportunities?